1. Introduction {#sec1-biomolecules-08-00169}
===============

Pancreatic cancer (PC) is one of the most fatal cancers with an extremely poor prognosis even in its early stages. It is found to be metastatic at presentation in approximately 50% of cases \[[@B1-biomolecules-08-00169],[@B2-biomolecules-08-00169]\]. It is the fourth leading cause of cancer-related death in the United States, and is second only to colorectal cancer as a cause of digestive cancer-related death \[[@B2-biomolecules-08-00169]\]. Carcinoma of the exocrine pancreas is a genetic disease that is caused by inherited and acquired mutations in specific cancer-associated genes \[[@B3-biomolecules-08-00169],[@B4-biomolecules-08-00169]\]. The patterns of genetic alterations identified in neoplasms of the pancreas are beginning to be integrated with tumor morphology and patient prognosis, and a new "molecular classification" of pancreatic neoplasia is slowly emerging \[[@B5-biomolecules-08-00169]\]. Acquired genetic mutations may represent new targets for the development of sensitive screening tests for early diagnosis of pancreatic cancer, particularly before it becomes invasive \[[@B6-biomolecules-08-00169],[@B7-biomolecules-08-00169]\].

Neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) was initially identified by its developmentally regulated expression pattern in early embryonic, but not adult, mouse brain \[[@B8-biomolecules-08-00169]\]. Overexpression of NEDD9 protein has now been strongly linked to poor prognosis in various types of cancers, as well as resistance to first-line chemotherapeutics \[[@B9-biomolecules-08-00169],[@B10-biomolecules-08-00169],[@B11-biomolecules-08-00169],[@B12-biomolecules-08-00169],[@B13-biomolecules-08-00169],[@B14-biomolecules-08-00169]\]. There are few articles in the literature about the association of NEDD9 and PC \[[@B15-biomolecules-08-00169],[@B16-biomolecules-08-00169],[@B17-biomolecules-08-00169]\]. It was shown that higher NEDD9 levels were significantly correlated with clinical staging, lymph node metastasis and histological differentiation and patients with a higher NEDD9 expression had a significantly shorter survival time than those patients with lower NEDD9 expression. NEDD9 could serve as an independent factor of poor prognosis in PC patients \[[@B15-biomolecules-08-00169]\]. MicroRNA-145 suppresses cell proliferation, invasion and migration in PC cells by targeting NEDD9 \[[@B16-biomolecules-08-00169]\] and baicalein, a flavone ingredient of *Scutellaria baicalensis* Georgi inhibits PC cell proliferation and invasion via suppression of NEDD9 expression and its downstream Akt and extracellular regulated kinase (ERK) signaling pathways \[[@B17-biomolecules-08-00169]\]. The aim of this study was to investigate the expression and prognostic significance of NEDD9 in PC patients.

2. Materials and Methods {#sec2-biomolecules-08-00169}
========================

2.1. Characteristics of the Patients and the Disease {#sec2dot1-biomolecules-08-00169}
----------------------------------------------------

The serum samples of the 32 pancreatic cancer patients with histologically confirmed diseases who were referred to Istanbul University Institute of Oncology and Bakirkoy Dr Sadi Konuk Training and Research Hospital from February 2011 to October 2014 were obtained. The patients had not received chemotherapy and/or radiotherapy over the last 6 months. The stage of the disease was determined according to the American Joint Committee on Cancer (AJCC) and International Union against Cancer (UICC) staging systems. Prior to onset of the treatment, the patients had been processed through a detailed assessment including clinical history, physical examination, and a series of blood tests, such as tumor markers, lactate dehydrogenase, and complete blood count. Investigations were carried out following the rules of the Declaration of Helsinki of 1975, which was revised in 2013. Institutional review board of Istanbul University Institute of Oncology in 2014 with the number 299 was obtained before the study.

During a median follow-up of 16.5 weeks (range: 1--187 weeks) while 10 patients (31%), experienced disease progression, 21 of the remaining patients (66%) died. Median progression free survival (PFS) and overall survival (OS) of the whole group were 12.0 ± 2.4 weeks (95% CI = 7--17 weeks) and 27.0 ± 7.3 weeks (95% CI = 13--41 weeks), respectively. While 6-months OS rates were 51.1% (95% CI = 33.3--68.9). There were liver metastasis in 16 (50%), abdominal implants in 3 patients, abdominal lymphadenopathy (LAP) in 3, lung in 2, and surrenal in 1 patient. Progression sites were liver in 6 patients, locally in 4 patients, and abdominal LAP in 1 patient.

2.2. Statistical Analysis {#sec2dot2-biomolecules-08-00169}
-------------------------

SPSS for Windows version 21.0 (SPSS Inc., Chicago, IL, USA) was employed for data analysis. Continuous variables were categorized using median values as cut-off point. Relationships and comparisons of several clinical/laboratory variables were evaluated via nonparametric tests. Mann--Whitney U-test was used to assess the serum levels between the subgroups. Overall survival was calculated from the date of first admission to the clinics to disease-related death or date of last contact with the patient or any family member. Progression-free survival was calculated from the date of admission to the date of first radiologic progression with/without elevated serum tumor marker. The Kaplan--Meier method was used for the estimation of survival distribution and differences in PFS and OS were assessed by the log-rank statistics. All statistical tests were carried out two-sided and a *p*-value ≤ 0.05 was considered statistically significant.

3. Results {#sec3-biomolecules-08-00169}
==========

In a three years period, 32 patients with a pathologically confirmed diagnosis of PC were enrolled in this study. The baseline histopathological characteristics and the demographic characteristics of the patients are listed in [Table 1](#biomolecules-08-00169-t001){ref-type="table"}. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men (n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx were CTx-responsive. Surgery was performed in six (18.7%) patients; three (9%) patients underwent pancreaticoduodenectomy and three (9%) patients had palliative surgery. Serum levels of laboratory parameters in patients were shown in [Table 2](#biomolecules-08-00169-t002){ref-type="table"}.

The levels of serum NEDD9 assays in patients with PA and healthy controls are shown in [Table 3](#biomolecules-08-00169-t003){ref-type="table"}. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (*p* = 0.03) ([Figure 1](#biomolecules-08-00169-f001){ref-type="fig"}).

[Table 4](#biomolecules-08-00169-t004){ref-type="table"} shows the correlation between the serum levels of NEDD9 and clinicopathological factors. Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, LDH levels were found to be significant prognostic factors (*p* = 0.006, *p* \< 0.001, and *p* \< 0.001, respectively) ([Table 5](#biomolecules-08-00169-t005){ref-type="table"}). However, serum NEDD9 levels had no significantly effect on PFS and OS (*p* = 0.71 and *p* = 0.58, respectively) ([Table 5](#biomolecules-08-00169-t005){ref-type="table"} and [Table 6](#biomolecules-08-00169-t006){ref-type="table"} and [Figure 2](#biomolecules-08-00169-f002){ref-type="fig"} and [Figure 3](#biomolecules-08-00169-f003){ref-type="fig"}).

4. Discussion {#sec4-biomolecules-08-00169}
=============

Pancreatic cancer (PC) is a highly lethal malignancy. Extensive research is being conducted to identify novel diagnostic, predictive, and prognostic biomarkers for PC \[[@B18-biomolecules-08-00169]\]. NEDD9 supports oncogenic signaling in a number of solid and hematologic tumors. Aurora A kinase (AURKA) is overexpressed in 96% of human cancers and is considered an independent marker of poor prognosis. NEDD9 depletion destabilizes AURKA and heightens the efficacy of Aurora A inhibitors and it has implications for treatment of metastatic solid tumors \[[@B19-biomolecules-08-00169]\]. NEDD9 has been found to be diagnostic, prognostic, and predictive in different kinds of tumor types \[[@B12-biomolecules-08-00169],[@B20-biomolecules-08-00169],[@B21-biomolecules-08-00169],[@B22-biomolecules-08-00169]\].

Little is known about the role of NEDD9 in PC but available data suggest elevated NEDD9 levels have been found in PC patients and it can have a prognostic role \[[@B15-biomolecules-08-00169],[@B16-biomolecules-08-00169],[@B17-biomolecules-08-00169],[@B18-biomolecules-08-00169],[@B20-biomolecules-08-00169]\]. High levels of expression of NEDD9 were significantly correlated with clinical staging, lymph node metastasis, and histological differentiation in PC patients \[[@B15-biomolecules-08-00169]\]. NEDD9 expression was not statistically correlated with tumor stage and grade, gender, or patient survival in another study done by Radulović et al. \[[@B18-biomolecules-08-00169]\].

Novel therapeutic agents are being investigated in PC. Not only the tumor cells but also the stroma is very important in PC. Immunotherapeutic options are limited and we are still using various kinds of chemotherapies. MicroRNA-145 suppresses cell proliferation, invasion and migration in PC cells by targeting NEDD9 \[[@B16-biomolecules-08-00169]\]. NEDD9 increases the invasiveness of solid tumors such as gastric cancer, ovarian cancer, and glioblastoma \[[@B14-biomolecules-08-00169],[@B20-biomolecules-08-00169],[@B23-biomolecules-08-00169]\]. There is growing evidence that NEDD9 is itself nononcogenic but changes in expression of NEDD9 (most commonly elevation of expression) are common features of tumors, and directly impact tumor aggressiveness, metastasis, and response to at least some targeted agents inhibiting NEDD9-interacting proteins. These data strongly support the relevance of further development of NEDD9 as a biomarker for therapeutic resistance \[[@B24-biomolecules-08-00169]\].

5. Conclusions {#sec5-biomolecules-08-00169}
==============

According to these data, in our study, we found out that NEDD9 can be used as a diagnostic marker for patients with PC but it has no prognostic role. The limitation of our study is the small sample size.
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biomolecules-08-00169-t001_Table 1

###### 

Characteristics of the patients and disease.

  Variables                                                 *n*
  --------------------------------------------------------- -------------
  No. of patients                                           32
  Age (years): Median (range)                               61 (38--84)
  Gender: Male/Female                                       20/12
  Smoking ^a^: Yes/No                                       17/12
  Alcohol intake ^a^: Yes/No                                4/26
  Comorbidity ^a^: Yes/no                                   20/10
  Weight loss ^a^: Yes/no                                   16/6
  Jaundice: Yes/no                                          7/25
  Performans status ^a^: 0/1/2/3                            6/13/6/6
  Surgery Type ^aa^: Whipple surgery/palliative surgery     3/3
  Tumor size ^a^: \<Small (\<40 mm)/≥large (≥40 mm)         14/13
  Site of lesion: Head/Corpus-tail                          21/11
  Response to chemotheraphy: Yes (PR + SD)/no(PD)/unknown   7/7/3
  Metastasis (*p*): Yes/no                                  18/14

^a^ Patients with unknown data concerning the variables are not included in the analysis. ^aa^ In 14 patients with nonmetastatic. PR: partial response; SD: stable disease; PD: progressive disease

biomolecules-08-00169-t002_Table 2

###### 

Serum levels of laboratory parameters in patients.

  Variables                                Values of n (%)
  ---------------------------------------- -----------------
  WBC ^a^                                  
  High (\>10,000)/normal (\<10,000)        5/25
  Hemoglobin ^a^                           
  Low (\<12)/normal (\>12)                 11/19
  PLT ^a^                                  
  Low (\<150,000)/normal (\>150,000)       4/26
  Lactate dehydrogenase ^a^                
  High (\>450 IU/mL)/normal (\<450 IU/mL   3/23
  Albumin ^a^                              
  Low (\<4 g/dL)/normal (\>4 g/dL)         20/9
  Carcinoembryonic antigen ^a^             
  High (\>5 ng/mL)/normal (\<5 ng/mL)      12/13
  CA19.9 ^a^                               
  High (\>38 U/mL)/normal (\<38 U/mL)      24/5

^a^ Patients with unknown data concerning the variables are not included in the analysis. WBC: white blood cell; PLT: platelet; IU: international unit; CA: carbohydrate antigen.

biomolecules-08-00169-t003_Table 3

###### 

The values of serum marker levels in pancreatic cancer patients and healthy controls.

                  Patients (*n* = 32)   Controls (*n* = 20)                               
  --------------- --------------------- --------------------- --------- ----------------- ---------
  Marker          Median                Range                 Median    Range             *p*
  NEDD9 (pg/mL)   1168.30               770.70--7523.11       1048.21   659.24--1256.54   0.03 \*

\* *p* ≤ 0.05.

biomolecules-08-00169-t004_Table 4

###### 

Comparisons of serum marker levels according to various clinical/laboratory parameters.

  -----------------------------------------------------------------------------
  Variables                        Values of *n*   NEDD9 (pg/mL)\
                                                   Median (Range)
  -------------------------------- --------------- ----------------------------
  Age patients (*p*)                               0.89

  Young (\<60)                     13              1169.93 (880.57--3936.74)

  Older (\>60)                     19              1166.67 (770.7--7523.11)

  Gender (*p*)                                     0.64

  Male                             20              1180.56 (770.70--7523.11)

  Female                           12              1090.69 (904.46--5525.55)

  Smoking (*p*)                                    0.79

  Yes                              17              1130.72 (770.70--7523.11)

  No                               12              1168.30 (904.46--6868.61)

  Alcohol intake (*p*)                             0.86

  Yes                              4               1078.87 (880.57--6946.47)

  No                               26              1148.70 (770.70--7523.11)

  Comorbidity (*p*)                                0.36

  Yes                              20              1180.56 (821.66--6946.47)

  No                               10              1030.31 (770.70--7523.11)

  PS (*p*)                                         0.9

  Good (0--1)                      19              1169.93 (770.70--7523.11)

  Worse (2--4)                     12              1148.70 (880.57--6946.47)

  Weight loss (*p*)                                0.88

  Yes                              16              1128.27 (770.70--7523.11)

  No                               6               1365.28 (821.66--6946.47)

  Jaundice (*p*)                                   0.26

  Yes                              7               1014.71 (880.57--7523.11)

  No                               25              1191.18 (770.70--6946.47)

  Surgery (*p*)                                    0.85

  Yes                              6               1443.63 (821.66--1965.69)

  No                               26              1148.70 (770.70--7523.11)

  Localization (*p*)                               0.86

  Head                             21              1169.93 (821.66--7523.11)

  Corpus-tail                      11              1125.82 (770.70--6868.61)

  Tumor size (*p*)                                 0.7

  Small (\<40 mm)                  14              1235.30 (821.66--7523.11)

  Large (≥40 mm)                   13              1169.93 (770.70--6868.61)

  Metastasis (*p*)                                 0.43

  Yes                              18              1084.97 (770.70--6946.47)

  No                               14              1433.01 (821.66--7523.11)

  Liver metastasis (*p*)                           0.35

  Yes                              16              1147.88 (904.46--6946.47)

  No                               2               966.56 (770.70--5525.55)

  Hemoglobin (*p*)                                 0.95

  Low                              11              1166.67 (952.23--6868.61)

  Normal                           19              1169.93 (770.70--7523.11)

  WBC (*p*)                                        0.28

  High                             5               1736.93 (904.46--6868.61)

  Normal                           25              1130.72 (770.70--7523.11)

  PLT (*p*)                                        0.04 \*

  Low                              4               1247.55 (770.70--7523.11)

  Normal                           26              959.40 (821.66--1130.72)

  Albumin (*p*)                                    0.6

  Low                              20              1247.55 (770.70--7523.11)

  Normal                           9               1066.99 (918.79--6868.61)

  Lactate dehydrogenase (*p*)                      0.32

  High                             3               3936.74 (952.23--6868.61)

  Normal                           23              1169.93 (821.66--7523.11)

  Carcinoembryonic antigen (*p*)                   0.74

  High                             13              1150.33 (770.70--6946.47)

  Normal                           12              1191.18 (821.66--6868.61)

  CA 19.9 (*p*)                                    0.04 \*

  High                             24              1965.69 (1066.99--6946.47)

  Normal                           5               1148.70 (770.70--6868.61)

  Response to chemotherapy (*p*)                   0.85

  Yes (PR + SD)                    7               1166.67 (918.79--1990.20)

  No (PD)                          7               1044.12 (821.66--5525.55)
  -----------------------------------------------------------------------------

\* *p* ≤ 0.05.

biomolecules-08-00169-t005_Table 5

###### 

Univariate analyses of serum marker progression-free survival.

  -------------------------------------------------------------------
  Parameters     *N* of Events/Total *N*   Survival (Weeks)\   *p*
                                           Median (±SD)        
  -------------- ------------------------- ------------------- ------
  All patients   10/32                     12 (2.4)            

  NEDD9                                                        

  \<Median       5/16                      13.0 (3.3)          0.71

  \>Median       5/16                      12.0 (4.4)          
  -------------------------------------------------------------------

biomolecules-08-00169-t006_Table 6

###### 

Univariate analyses of overall survival.

  --------------------------------------------------------------------------------------------------------------
  Parameters                 N of Events/Total N   Survival (Weeks)\   6-Month Survival (%) (±SD)   *p*
                                                   Median (±SD)                                     
  -------------------------- --------------------- ------------------- ---------------------------- ------------
  All patients               21/32                 27.0 (7.3)          51.1 (9.1)                   

  Age patients                                                                                      

  Young (\<60)               9/13                  31.0 (12.3)         68.4 (13.1)                  0.33

  Older (\>60)               12/19                 16.0 (4.1)          39.7 (11.5)                  

  Gender                                                                                            

  Male                       11/20                 44.0 (23.5)         52.5 (11.6)                  0.21

  Female                     10/12                 17.0 (13.9)         50.0 (14.4)                  

  Smoking                                                                                           

  Yes                        11/17                 17.0 (11.5)         46.3 (15.0)                  0.35

  No                         8/12                  39.0 (20.3)         57.8 (12.2)                  

  Alcohol intake                                                                                    

  Yes                        3/4                   1.0 (NR)            NR                           0.006 \*

  No                         16/26                 31.0 (9.5)          59.2 (10.0)                  

  Comorbidity                                                                                       

  Yes                        13/20                 17.0 (12.2)         48.2 (11.4)                  0.53

  No                         6/10                  31.0 (9.6)          68.6 (15.1)                  

  P                                                                                                 

  Good (0--1)                8/19                  44.0 (8.6)          71.6 (10.8)                  \<0.001 \*

  Worse (2--4)               12/12                 7.0 (4.3)           25.0 (12.5)                  

  Weight loss                                                                                       

  Yes                        13/16                 11.0 (1.8)          34.7 (12.3)                  0.11

  No                         2/6                   39.0 (27.7)         83.3 (15.2)                  

  Jaundice                                                                                          

  Yes                        7/7                   11.0 (9.2)          28.6 (17.1)                  0.09

  No                         14/25                 31.0 (8.4)          57.8 (10.2)                  

  Surgery                                                                                           

  Yes                        4/6                   27.0 (7.4)          51.6 (10.1)                  0.78

  No                         17/26                 15.0 (16.7)         50.0 (20.4)                  

  Localization                                                                                      

  Head                       13/21                 27.0 (10.0)         53.6 (11.4)                  0.2

  Corpus-tail                8/11                  12.0 (7.8)          45.5 (15.0)                  

  T size                                                                                            

  Small (\<40 mm)            9/14                  31.0 (9.3)          64.3 (12.8)                  0.28

  Large (\>40 mm)            9/13                  12.0 (1.7)          34.6 (13.8)                  

  Metastasis                                                                                        

  Yes                        12/18                 12.0 (6.0)          40.7 (12.3)                  0.12

  No                         9/14                  31.0 (11.4)         64.3 (12.8)                  

  Liver metastasis                                                                                  

  Yes                        11/16                 12.0 (5.6)          39.1 (13.1)                  0.31

  No                         2/2                   17.0 (12.3)         NR                           

  Hemoglobin                                                                                        

  Low                        9/11                  15.0 (5.1)          36.4 (14.5)                  0.06

  Normal                     10/19                 31.0 (11.6)         65.6 (11.4)                  

  WBC                                                                                               

  High                       3/5                   11.0 (3.0)          NR                           0.36

  Normal                     16/25                 31.0 (13.4)         56.0 (9.9)                   

  PLT                                                                                               

  Low                        2/4                   57.0 (NR)           NR                           0.6

  Normal                     17/26                 27.0 (8.0)          51.0 (10.0)                  

  Albumin                                                                                           

  Low                        14/20                 17.0 (7.9)          45.7 (11.8)                  0.07

  Normal                     4/9                   39.0 (NR)           77.8 (13.9)                  

  Lactate dehydrogenase                                                                             

  High                       3/3                   7.0 (0.0)           NR                           \<0.001 \*

  Normal                     13/23                 39.0 (7.3)          68.3 (9.9)                   

  Carcinoembryonic antigen                                                                          

  High                       10/13                 12.0 (3.2)          37.5 (14.7)                  0.29

  Normal                     8/12                  31.0 (5.8)          61.5 (13.5)                  

  CA 19                                                                                             

  High                       17/24                 27.0 (7.4)          51.6 (10.6)                  0.13

  Normal                     2/5                   NR                  NR                           

  Response to chemotherapy                                                                          

  Yes (PR + SD)              4/7                   31.0 (2.6)          71.4 (17.1)                  0.25

  No (PD)                    5/7                   39.0 (2.8)          57.1 (18.7)                  

  NEDD9                                                                                             

  \<Median                   10/16                 27.0 (14.0)         56.3 (12.4)                  0.58

  \>Median                   11/16                 16.0 (4.4)          45.0 (13.3)                  
  --------------------------------------------------------------------------------------------------------------

\* *p* ≤ 0.05.
